FDA grants full approval to AbbVie/ImmunoGen drug Elahere (NYSE:ABBV)

Published on 22 Mar 2024 on Seeking Alpha

The FDA has granted full approval to AbbVie's (ABBV) ovarian cancer drug Elahere, which it acquired...

Read the rest of the article

Start tracking your investments with Statfolio

Launched on 12/16/2016, the Pacer US Cash Cows 100 ETF (COWZ) is a passively managed exchange tra...

Zacks via Yahoo Finance 23 Apr 2024

AbbVie ABBV will report first-quarter 2024 results on Apr 26, before market open. In the last rep...

Zacks via Yahoo Finance 22 Apr 2024

AbbVie (ABBV) stock gains as the company's JAK inhibitor, upadacitinib, succeeds in a Phase 3 tri...

Seeking Alpha 18 Apr 2024

AbbVie's (ABBV) buyout target, Cerevel Therapeutics (CERE), announced positive data for its...

Seeking Alpha 18 Apr 2024

CVS Health's (CVS)decision to drop coverage for Humira and favor its cheaper biosimilars is hurti...

Seeking Alpha 17 Apr 2024

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you m...

Zacks via Yahoo Finance 16 Apr 2024

In this article, we will take a look into AbbVie Inc's (NYSE:ABBV) DCF analysis, a reliable and d...

GuruFocus.com via Yahoo Finance 16 Apr 2024

In this article, we discuss 15 best monthly dividend stocks to buy right now. You can skip our de...

Insider Monkey via Yahoo Finance 16 Apr 2024

In this article, we discuss 12 best dividend stocks with high upside potential. You can skip our ...

Insider Monkey via Yahoo Finance 16 Apr 2024

Despite the entry of discounted biosimilars, AbbVie (ABBV) has maintained 96% market share for it...

Seeking Alpha 13 Apr 2024